… agent, and romidepsin [35]. The overall response rates in all, non–T cell and T cell lymphoma
… myeloid cells at different stages of development [83, 84]. Its expression was reported in NK/…

… T-cell lymphoma (PTCL) is a heterogeneous group of generally aggressive non-Hodgkin
lymphoma … almost 10% of all non-Hodgkin lymphomas (NHL). PTCLs are further histologically …

… those who were treated with romidepsin had an improved … of developing a true T-cell
lymphoma directed treatment programme. Layering these novel and emerging drug development …

… T-cell lymphoma. We found that romidepsin was synergistic with doxorubicin in growth
inhibition and apoptosis induction in both cutaneous T-cell lymphoma (CTCL) cell lines and …

… After central review, diagnoses were AITL or related neoplasms of follicular helper T-cell (TFH)
derivation (follicular T-cell lymphoma or nodal PTCL with TFH phenotype) in 201 (47.7%) …

… Given the results seen with tenalisib being combined with romidepsin, the authors believe
that the development of the combination should still be explored in both patients with PTCL …

… Peripheral T-cell lymphoma (PTCL) is a group of malignant tumors with heterogeneous …
to catch up with the drug development progress of B-cell lymphoma and deepen the …

… tumor suppressor gene transcription, growth inhibition, cell cycle regulation and
apoptosis.Romidepsin received FDA approval in 2009 for cutaneous T-cell lymphoma (CTCL) after …

… required for normal T-cell development and differentiation … -line treatment of PTCL, the role
of romidepsin most certainly … Novel combinations of romidepsin with more targeted agents …

… and duvelisib based on whether patients did or did not develop … T cell or B cell compartments
when stratified by development … who did not develop toxicity, treatment with romidepsin and …